Palatin Technologies (FRA:PTN) Total Current Assets : €11.23 Mil (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Palatin Technologies Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Palatin Technologies's total current assets for the quarter that ended in Dec. 2023 was €11.23 Mil.

Palatin Technologies Total Current Assets Historical Data

The historical data trend for Palatin Technologies's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palatin Technologies Total Current Assets Chart

Palatin Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Current Assets

Get a 7-Day Free Trial

92.41

74.23

54.70

32.73

15.07

Palatin Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															28.84	22.64	15.07	9.19	11.23

Palatin Technologies Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Palatin Technologies's Total Current Assets for the fiscal year that ended in Jun. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	10.136	+	2.691	+	0.485	+	1.753
	=	15.07

Palatin Technologies's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	8.698	+	2.151	+	0	+	0.38
	=	11.23

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Palatin Technologies (FRA:PTN) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Palatin Technologies's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8.698	-	22.869	+	0.75 * 2.151	+	0.5 * 0
=	-12.56

Palatin Technologies Total Current Assets Related Terms

Thank you for viewing the detailed overview of Palatin Technologies's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Palatin Technologies (FRA:PTN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palatin Technologies Inc (FRA:PTN) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

PTN:USA

Address

4B Cedar Brook Drive, Cranbury, NJ, USA, 08512

Website

https://www.palatin.com

Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.